Corporate Social Performance of Indonesian State-Owned and Private Companies

The objectives of this study are to analyze the difference of corporate social performance between State-owned and private companies in Indonesia, and also to analyze the correlation between the corporate social performance (CSP) and the corporate financial performance by using company size, and institutional ownership as control variables. The population of this study is Indonesian state owned and private companies in the year of 2001-2004. Purposive sampling was used in this study, and final samples are 461 companies. The CSP or CSR (Corporate social responsibility) score is measured by content analysis of corporate annual report using seven item developed by Michael Research Jantzi Research Associate, Inc. The data is tested by independent t-test to determine the mean difference and by using partial correlation test to know the correlation between the corporate social performance and financial performance. The results of this study are that there is no significant difference mean of corporate social performance between state-owned and private owned companies in Indonesia. In addition, the correlation test indicates that there is no association between corporation social performance and financial performance both in SOCs and POCs

Characterisation of Asystasia Gangetica and Phyllanthus Niruri Extracts: Total Phenolic Content, Antioxidant and Antibacterial Activities

Antioxidant plays a significant role in inhibiting and scavenging free radicals, which protects human against infection and degenerative diseases. Nowadays, most studies focus on “natural antioxidants†from herbs due to safe therapeutic. In this study, performance on different extraction methods, i.e. Soxhlet, cold maceration and traditional extraction method assisted with ultrasonic-assisted extraction (UAE) for Asystasia gangetica leaves and Phyllanthus niruri plant are investigated by means of antioxidant, total phenolic content and antibacterial activity. The extracts were characterized for its antioxidant activity and total phenolic content by means of DPPH radical scavenging method and Folin-Ciocalteau reagent respectively. Optimization studies were carried out on combined cold-maceration and UAE extraction method by using Response Surface Method. Then, the optimized extracts were further characterized for antibacterial activity using Escherichia coli and Staphylococcus epidermidis by the agar disc diffusion method. Sample containing cold macerated A. gangetica and P. niruri indicates the highest antioxidant property as it contains the highest percentage of DPPH scavenging activity (59.57% and 51.14% respectively). While, the total phenolic content of macerated A. gangetica and P. niruri are 2.73 mg GAE/g and 2.68 mg GAE/g respectively. Consequently, after the determination of highest percentage of DPPH scavenging activity, the extracts were further optimized using UAE. From the optimization, the optimum condition was determined to be power of 17.57±0.01W and time of 5.83±0.01minutes for A. gangetica while, the power of 98.14±0.01W and 0.17±0.01minutes for P. niruri. Both optimized extracts showed potent antibacterial activity with high degree of antibacterial against E. coli. In conclusion, combination of cold maceration and UAE method increase the amount of antioxidant from extracts of A. gangetica and P. niruri. The finding from this study can be useful in pharmaceutical and cosmeceutical industries.   Keywords: Asystasia gangetica, Phyllanthus Niruri, Antioxidant Activity, Total Phenolic Content, Antibacterial Activity

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Merdeka Belajar Merdeka Mengajar

Kebijakan pemerintah “Merdeka Belajar, Kampus Merdeka” tentu menimbulkan respon tersendiri bagi para dosen selaku akademisi bagaimana menyikapi, merencanakan, menyusun dan mengimplementasikan sistem dan model belajar yang paling sesuai dengan kebijakan tersebut. Dan di buku Antologi inilah akan dijumpai berbagai pandangan, pemikiran, dan juga mungkin gambaran usulan untuk mengimplementasikan kebijakan MBKM di era informasi teknologi yang sangat cepat berubah dewasa ini. Sebagai pendidik profesional, para dosen tentu memiliki kiat dan cara tersendiri untuk bisa menghasilkan output lulusan peserta didik yang benar-benar sesuai dengan tujuan dan target kebijakan MBKM tersebu